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Abstract:  The effects of streptozotocin (STZ)-induced diabetes on induction of hepatic preneoplastic lesions by
diethylnitrosamine (DEN) were investigated in male Fischer rats.  A single dose of STZ was injected intravenously either
2 weeks before or after initiation with DEN.  The blood glucose levels were significantly elevated from 1 week after
STZ-injection until autopsy.  The numbers of GST-P positive foci at 1 week after DEN administration in the STZ-
injected rats were similar to those in the non-diabetic rats.  In contrast, both the numbers and areas of GST-P positive
foci > 2 mm in diameter 8 weeks after DEN administration were increased significantly in the rats treated with STZ after
DEN exposure compared with the non-diabetic control rats.  The results suggest that hepatic preneoplastic lesions
initiated with DEN are promoted by STZ treatment-inducing diabetes.    (J Toxicol Pathol 2010; 23: 125–131)
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Introduction
In recent years, epidemiological surveys have revealed
that diabetic patients are at high risk of developing a variety
of cancers1–4.  In particular for hepatocellular carcinoma
(HCC), diabetic individuals have a 2-4-fold elevated risk as
compared with their non-diabetic counterparts1–3, 5–10.  It is
considered that diabetes could be an independent risk factor
for HCC, separate from viral hepatitis and heavy alcohol
consumption5,8,10.  Although elevation of the fasting serum
glucose level4 or insulin11 has been suggested to be involved
in the underlying mechanisms, this has yet to be clarified in
detail.
Experimental studies on the effects of diabetes on hepa-
tocarcinogenesis have been limited.  There are two types of
animal model of diabetes, a spontaneous one and a drug-
induced one.  The streptozotocin (STZ)-induced diabetic rat
model is widely used12–14 as a model of Type-1 diabetes,
because STZ reduces insulin secretion by selectively
destroying pancreatic beta cells15.  In the present work, we
investigated the effect of diabetes due to STZ on diethylnit-
rosamine (DEN)-induction of rat hepatocarcinogenesis.
Materials and Methods
Animals
Male F344/Ducrj (Fischer) rats were obtained at 4 or 5
weeks of age from Charles River Laboratories Japan Inc.
(Atsugi, Japan) and used for the experiment after quarantine
and acclimation for 1 week.  The animals were individually
housed in stainless steel wire-mesh cages in an air condi-
tioned room (room temperature 23 ± 2°C, relative humidity
55 ± 10%, ventilation 10–20 times/h, and a 12 light/12 dark
cycle).  During the entire period of study, the rats were sup-
plied with pellet diet (CRF-1, Oriental Yeast Co., Ltd.,
Tokyo) and water ad libitum.
All experimental procedures were performed in accor-
dance with the Law for the Humane Treatment and Manage-
ment of Animals (Law No.105, 1973), “Basic policies for the
conduct of animal experiments in research institutions under
the jurisdiction of the Ministry of Health, Labor and Wel-
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fare, Japan” Notification of the Ministry of Health, Labor
and Welfare, Japan dated June 1, 2006, and basic policies for
the conduct of animal experiments in Mie Research Park of
Sanwa Kagaku Kenkyusho Co., Ltd.
Chemicals and preparation
STZ, obtained from Sigma Chemical Co., USA, was
dissolved in 0.05 M citrate buffer solution (pH: 4.5)16.  DEN,
obtained from Wako Pure Chemical Industries, Ltd., Osaka,
Japan, was diluted to 50 mg/ml in saline for use17.
Experiment protocols
Experiment 1:  In experiment 1, the effects of STZ-
induced diabetes on the induction of hepatic preneoplastic
lesions by DEN were investigated (Fig. 1).  Five-week-old
rats were randomly divided into three groups comprised of
15 rats/group.  The first and second groups were injected
with a single dose of STZ (35 mg/kg or 45 mg/kg in 0.05 M
citrate buffer) into the tail vein at 1 ml/kg at a speed of 0.15
ml/min for induction of diabetes18.  The third group was
given the vehicle in the same manner.  Two weeks later, all
rats were injected with a single dose of DEN at a dose of 200
mg/kg b.w.  intraperitoneally at  4 ml/kg to initiate hepato-
carcinogenesis.  At week 12, all rats were euthanized under
ether anesthesia.
Experiment 2:  In experiment 2, the effects of STZ-
induced diabetes particularly on the initiation step of hepato-
carcinogenesis were investigated by stopping the experiment
at 1 week after DEN exposure (Fig. 2).
Five-week-old rats were randomly divided into two
groups.  The 16 rats comprising  the first group were injected
with a single dose of STZ (45 mg/kg in 0.05 M citrate
buffer), whereas the 10 rats comprising the second group
were given the vehicle in the same manner as Experiment 1.
Two weeks later, all rats were injected with a single dose of
DEN (200 mg/kg) intraperitoneally, and 1 week later (week
3), all rats were euthanized under ether anesthesia.
Experiment 3:  The effects of STZ-induced diabetes on
the promotion stage of hepatocarcinogenesis resulting from
administration of DEN were investigated using a medium-
term rat liver bioassay for carcinogens17.
Six-week-old rats were randomly divided into four
groups comprised of 15 rats/group.  All rats were injected
with a single dose of DEN (200 mg/kg) intraperitoneally.
Two weeks later, the first and the second groups were
injected with a single dose of STZ (15 mg/kg or 30 mg/kg in
0.05 M citrate buffer) into the tail vein in the proportion of 1
ml/kg at a speed of 0.15 ml/min, which induced diabetes
(Fig. 3).  The third and the forth groups were given the vehi-
cle.  The forth group was fed powder diet containing 0.05%
phenobarbital for the following 6 weeks as a positive control
for promotion of hepatocarcinogenesis.
At week 3, all rats were subjected to two-thirds partial
hepatectomy to accelerate the carcinogenic process.  At week
8, all rats were euthanized under ether anesthesia (Fig. 3).
Experiment 4:  The effects of STZ-induced diabetes on
the promotion step of hepatocarcinogenesis by resulting
from administration of DEN without partial hepatectomy
were investigated.
Six-week-old rats were randomly divided into two
groups comprising 15 and 16 rats.  All rats were injected
with a single dose of DEN (200 mg/kg) intraperitoneally.
Two weeks later, the first group was injected with a single
dose of STZ (30 mg/kg in 0.05 M citrate buffer), whereas the
second group was given the vehicle.  At week 10, all rats
were euthanized under ether anesthesia (Fig. 4).
Measurement of blood glucose
One or 2 weeks after STZ administration and at
necropsy, blood samples were collected from the tail vein.
Fig. 1. Design of Experiment 1.
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The plasma glucose concentration was measured by the glu-
cose oxidase method using a Beckman glucose analyzer II
(Beckman Instruments, Fullerton, CA, USA).
Immunohistochemical examination of the glutathione
S-transferase placental form (GST-P)
Soon after sacrifice of the rats, livers were promptly
excised and weighed, and sections 3–4 mm thick were cut
from the right posterior lobe and fixed in ice-cold acetone for
immunohistochemical examination of GST-P.  The avidin-
biotin complex method (Vectastain Elite Kit, Vector Labora-
tories Inc.) was used to demonstrate GST-P positive cell foci
using a specific antibody (MBL, Nagoya, Japan).
The numbers and areas of GST-P positive foci were
measured quantitatively using the multipurpose image pro-
cessor IPAP-WIN (Sumika Technoservice Corporation,
Hyogo, Japan).
Statistical analysis
Blood glucose, final body weight, liver weight and the
data expressed as numbers and areas of GST-P positive foci
per unit area of the liver slices were assessed by comparing
the values between groups.  Statistical analyses were carried
out using the Student’s t-test.
Results
Experiment 1
Blood glucose levels in STZ-injected groups were STZ
dose-dependently and significantly elevated from 2 weeks
after the STZ treatment until the end of the experiment
(Table 1).  The body weights of the STZ-injected groups,
particularly in the 45 mg/kg STZ-injected group, were con-
sistently lower than those of the non-diabetic control group.
The relative liver weights of the STZ-injected groups also
showed significant increases when compared with the non-
diabetic control group.  Both  the numbers and areas of GST-
P positive foci > 2 mm in diameter were increased STZ dose-
dependently and significantly in the STZ-injected groups
when compared with the non-diabetic control group (Table
1, Fig. 5).  In particular the 45 mg/kg STZ-injected group
showed a fivefold or sixfold increase when compared with
the non-diabetic control group (Table1).
Experiment 2
In the 45 mg/kg STZ-injected group, significant eleva-
tion of the blood glucose level and significant reduction of
body weight gain were observed.  The absolute and relative
liver weights of the STZ-injected group showed significant
Fig. 3. Design of Experiment 3.
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increases when compared with the control group.
There was no significant difference in the numbers of
GST-P-positive foci per unit area between the STZ-injected
group and the non-diabetic control group (data not shown).
Experiment 3
During the experiment, 4 normal control rats, 3 of 15
mg/kg STZ-injected rats, 7 of 30 mg/kg STZ-injected rats
and 4 phenobarbital administered rats died from surgical
error or post-surgical debilitation.  These dead rats were
excluded from the effective numbers in the experimental
results.
There was no difference in the blood glucose levels
between the 15 mg/kg STZ-injected group and the normal
control group (Table 2).  However, significantly elevated
blood glucose was observed in the 30 mg/kg STZ-injected
group.  Each STZ-injected group showed similar changes of
body weight as in the normal control group throughout the
experimental period.  There were no differences in the liver
weights between the 15 mg/kg STZ-injected group and the
normal control group.  However, significant increases of
both absolute and relative liver weights were observed in the
30 mg/kg STZ-injected group and the phenobarbital admin-
istered group (Table 2).
The numbers and areas of GST-P positive foci in the
STZ-injected groups showed a tendency to increase, but did
not significantly differ from the control values (Table 2).  In
the phenobarbital group, the numbers and areas of GST-P
positive foci showed threefold and fourfold increases,
respectively, when compared with the controls (Table 2).
Experiment 4
In the STZ-injected group, significantly elevated blood
glucose and reduced body weight gain were observed (Table
3).  The relative liver weights of the STZ-injected group
were twofold higher than the non-diabetic control values.
Six of  the STZ-injected rats showed discoloration of the
liver, indicating deposition of fat.
Both the numbers and areas of GST-P positive foci in
the STZ-injected group showed threefold and fourfold
increases respectively, when compared with the non-diabetic
control values (Table 3).
Discussion
In the present study, STZ treatment steadily increased
the blood glucose levels throughout the experimental period,
pointing to induction of a continuous state of diabetes.  Fur-
thermore, development of GST-P positive foci, well esta-
bished rat hepatic preneoplastic lesions, was enhanced in the
diabetic rats and was STZ-dose dependent.
Examination of whether the increase of hepatic preneo-
plastic lesions in STZ-induced diabetic rats was attributable
to accelerated initiation by DEN or promotion of the growth
of initiated preneoplastic lesions, suggested that the latter
was the more important, because the numbers of GST-P pos-
itive foci 1 week after DEN administration (Fig. 2) in the
Table 1. Blood Glucose Levels, Body and Liver Weights, and Quantitative Values of GST-P Positive Foci in Experiment 1
Group Treatment No. of  Blood glucose (mg/dL) Final body Liver weight GST-P positive foci
rats Week 2 Week 12 weight (g) Absolute (g) Relative (%) No./cm2 Area (mm2)/cm2
1 35 mg/kg STZ +DEN 15 339 ±129*** 316 ± 139*** 205.2  ± 28.0*** 8.0 ± 0.6* 4.0 ± 0.6*** 3.0 ± 1.9** 0.22 ± 0.18**
2 45 mg/kg STZ +DEN 15 503 ±77*** 450 ± 35*** 152.6 ± 25.1*** 7.3 ± 0.7 4.9 ± 0.7*** 5.2 ± 2.2*** 0.31 ± 0.16***
3 DEN  control 15 127  ± 6 108 ± 2 251.2 ± 13.6 7.5 ± 0.4 3.0 ± 0.1 1.0 ± 1.0 0.05 ± 0.06
Values are means ± SD.  *,**,*** Significantly different from the DEN control group values at p <0.05, p <0.01, p <0.001, respectively.
Fig. 5. Representative GST-P foci in the DEN control (a) and DEN
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STZ-injected group were thus similar to those in the non-dia-
betic control group.  We then utilized the medium-term rat
liver bioassay for carcinogens to examine the promotion
potential of STZ-induced diabetes.  Development of GST-P
positive foci was only slightly enhanced in the STZ-injected
groups, without statistical significance.  The decrease of the
blood glucose levels in diabetic rats after partial hepatec-
tomy was thought to be the cause of this result.  Therefore,
we conducted an additional experiment without partial hepa-
tectomy to reexamine the promotion effect of STZ-induced
diabetes, in which significant increases of the numbers and
areas of GST-P positive foci were observed in the STZ-
injected group.  These data clearly indicated that STZ-
induced diabetes promotes development of hepatic preneo-
plastic lesions in rats.
Saha et al.19 previously reported that the total number
and size of hepatic hyperplastic nodules was increased by
STZ administration either before or after initiation with
DEN.  Furthermore, both the hepatic GST and microsomal
GGT activities were significantly increased in these STZ
administered rats.  Because increases of these biomarkers
were more pronounced in rats given STZ after DEN initia-
tion, they proposed that the diabetic condition in rats acceler-
ates DEN-induced hepatocarcinogenesis.  Our results are in
agreement.  STZ-induced diabetic rats have been widely
used as a type 1 diabetic model because STZ selectively
destroys beta cells in the pancreatic islands, resulting in
reduction of insulin secretion.  Together with the data of
Saha et al.19, our findings clearly demonstrate that high
blood glucose conditions in diabetic rats enhance liver car-
cinogenesis after exposure to a carcinogenic substance.
In humans, type 2 diabetes accounts for the majority of
all diagnosed cases of diabetes.  The level of insulin is typi-
cally high during the development and early stages of type 2
diabetes.  Activation of the insulin receptor by its ligand, or
cross-activation of the insulin-like growth factor 1 receptor,
has been shown to be mitogenic and promote
tumorigenesis20.  Oshima et al.  investigated the effect of
insulin on liver tumorigenesis by DEN in STZ-induced dia-
betic rats using a medium-term rat liver bioassay for carcin-
ogens.  Significant increase in the area of hyperplastic liver
nodules was the outcome21.  Dombrowski et al.  demon-
strated that islet transplantation into the livers of STZ dia-
betic rats can induce hepatocellular preneoplastic lesions and
neoplasms at a high incidence after 22 months22.  They also
showed that islet transplantation into the livers of BB/Pfd
rats, which develop spontaneous autoimmune diabetes simi-
lar to human type 1 diabetes, caused hepatocellular
neoplasia23.  These results demonstrated that combined
hyperinsulinism and hyperglycemia may act as a carcino-
genic factor for the development of HCCs in diabetic rats.
STZ is known as a genotoxic chemical in rats24.  Dom-
browski et al.  confirmed that hepatocarcinogenesis in their
STZ diabetic model is independent from STZ22,23.  In the
present study, STZ did not accelerate initiation by DEN, and
preneoplastic lesions were not enhanced significantly by
STZ injection with partial hepatectomy.  Therefore, the
increase of the preneoplastic lesions in the STZ-injected
group without partial hepatectomy may be independent from
the genotoxicity of STZ.  We hypothesized that hyperglyce-
mia-mediated oxidative stress promoted preneoplastic
lesions.
In recent years, non-alcoholic steatohepatitis (NASH)
has received a great deal of attention as a nonviral cause of
hepatocarcinoma in humans25–27.  It is known that 25% of
NASH cases progress to cirrhosis through 10 years of fol-
low-up28, and the affected individuals may develop liver
cancer29,30.  NASH is considered to be caused by fatty depos-
its in the liver facilitated by an increase of insulin resistance
and is likely associated with additional hepatocyte damage
Table 2. Blood Glucose Levels, Body and Liver Weights and Quantitative Values of GST-P Positive Foci in Experiment 3
Group Treatment No. of Blood glucose (mg/dL) Final body Liver weight GST-P positive foci
rats Week 3 Week 8 weight (g) Absolute (g) Relative (%) No./cm2 Area (mm2)/cm2
1 DEN+15mg/kg STZ 12 129 ± 5 116 ± 3 234.7 ± 14.0 7.3 ± 0.8 3.1 ± 0.2 5.0 ± 3.1 0.36 ± 0.26
2 DEN+30mg/kg STZ 8 377 ± 75*** 219 ± 136** 228.9 ± 20.1 8.1 ± 0.6** 3.6 ± 0.5** 5.9 ± 2.6 0.44 ± 0.29
3 DEN control 11  123 ± 8 114 ±  6 224.7 ± 15.2 6.9 ± 0.8 3.1 ± 0.2 4.2 ± 2.5 0.27 ± 0.21
4 DEN+PB 11 – – 243.7 ± 9.9** 9.4 ± 0.5*** 3.9 ± 0.1*** 15.3 ± 4.0*** 1.05 ± 0.39***
Values are means ± SD.  **,*** Significantly different from the DEN control group values at p <0.01, p <0.001, respectively.
Table 3. Blood Glucose Levels, Body and Liver Weights, and Quantitative Values of GST-P Positive Foci in Experiment 4
Group Treatment No. of  Blood glucose (mg/dL) Final body Liver weight GST-P positive foci
rats Week 3 Week 10 weight (g) Absolute (g) Relative (%) No./cm2 Area (mm2)/cm2
1 DEN+STZ 30 mg/kg 15 362 ± 46*** 410 ± 101*** 133.6 ± 25.8*** 8.4 ± 1.5 6.6 ± 2.0*** 8.3 ± 3.7*** 0.66 ± 0.43***
2 DEN control 15 81 ± 67 7   ± 5 247.6 ± 14.1 7.6 ± 0.5 3.1 ± 0.1 2.5 ± 1.8 0.17 ± 0.15
Values are means ± SD. *** Significantly different from the DEN control group values at p <0.001.130 Diabetes Effects on Hepatocarcinogenesis
by oxidant stress31.  Many patients with NASH have hyper-
insulinemia linked to insulin resistance32,33.  Furthermore,
oxidant stress derived from hyperglycemia in diabetic
patients aggravates insulin resistance and increases inflam-
matory cytokines in the blood34,35.  Therefore, it is suggested
that hyperinsulinemia and hyperglycemia play a role in the
progression of hepatocellular carcinoma.  The STZ-induced
diabetic rats in our experiment showed increases of liver
weight and discoloration (fatty deposition), but similarities
to the pathological conditions of NASH and the involvement
of oxidant stress remain to be ascertained.
In conclusion, the present experiemental results demon-
strated that hepatic preneoplastic lesions initiated with DEN
are promoted by STZ-treatment inducing diabetes.  This
might be the case in type 2 diabetic patients, and our experi-
mental animal model might thus be of general use to study
the mechanisms underlying elevated hepatocarcinoma risk
in diabetic patients.
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